Trellus Health (TRLS)

Sector:

Health Care

Index:

FTSE AIM All-Share

2.13p
   
  • Change Today:
    -0.13p
  • 52 Week High: 9.20p
  • 52 Week Low: 2.13p
  • Currency: UK Pounds
  • Shares Issued: 161.51m
  • Volume: 0
  • Market Cap: £3.43m

Deal with Barclays    Trade now with Barclays Stockbrokers

Trellus Health launches direct-to-consumer offering in New York area

By Josh White

Date: Monday 28 Feb 2022

LONDON (ShareCast) - (Sharecast News) - Connected health platform operator Trellus Health announced the launch of its direct-to-consumer offering in the New York tri-state area on Monday, for people living with Crohn's disease and ulcerative colitis.
The AIM-traded firm said the service would provide its "resilience-based methodology" to support adult patients' clinical treatment plans through care coordination, behavioural skills training, expert disease education and remote patient monitoring.

It said the programme would include personalised whole-person care plans, the HIPAA-compliant 'TrellusElevate' digital platform, telehealth services, and remote access to an expert licenced care team, including a nurse educator, behavioural health counsellor, dietitian and resilience coach.

Initially, Trellus would offer enrolment for patients over the age of 17 in the states of New York, New Jersey and Connecticut, with plans to expand into more than 20 states by the end of the year.

The board said that, with more than 30 million residents, the tri-state area contained "one of the highest concentrations" of people living with IBD in the United States of around 250,000 patients.

Trellus said it was partnering with Connected Health Medicine to deliver telehealth clinical services using licensed healthcare professionals.

Fees to access and engage with the company's direct-to-consumer service would be paid directly by patients, or reimbursed by health insurance using existing current procedural terminology (CPT) codes with select commercial insurance plans.

It said direct-to-consumer pricing was lower on average than value-based business-to-business contract fees, and a discounted introductory monthly membership rate was being offered to build rapid awareness and recruitment.

As it previously said in its December update, Trellus' focus in 2022 would be on recruitment of direct-to-consumer patients, and the establishment of additional demonstration programmes and business-to-business contracts.

That, the board said, would enable Trellus to gather "real world evidence" to validate and reinforce the health quality and economic outcomes shown in the co-founders' published research, as well as informing further product development.

"IBD is a debilitating, incurable condition that requires behavioural support to cope with the complexity and challenges of daily living," said chief executive officer Monique Fayad.

"Trellus Health partners with IBD patients and their GI Providers, offering behavioural, nutritional and clinical monitoring support and tools beyond traditional episodic medical care, with the goal of empowering patients, improving outcomes and reducing the need for unplanned hospital and emergency room visits.

"Healthcare providers can look to Trellus as a trusted extension of their gastroenterology practice that helps improve care plan adherence and outcomes through remote patient monitoring and access to much needed whole-person care."

At 1310 GMT, shares in Trellus Health were up 3.36% at 30.49p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Trellus Health Market Data

Currency UK Pounds
Share Price 2.13p
Change Today -0.13p
% Change -5.56 %
52 Week High 9.20p
52 Week Low 2.13p
Volume 0
Shares Issued 161.51m
Market Cap £3.43m

Trellus Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.08% above the market average47.08% above the market average47.08% above the market average47.08% above the market average47.08% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Price Trend
94.29% below the market average94.29% below the market average94.29% below the market average94.29% below the market average94.29% below the market average
78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average
Income Not Available
Growth
23.83% below the market average23.83% below the market average23.83% below the market average23.83% below the market average23.83% below the market average
27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average

Trellus Health Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Trellus Health Key Personnel

CEO Marla Dubinsky

Top of Page